Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3 )

Vincent Leroy; Peter Angus; Jean-Pierre Bronowicki; Gregory J Dore; Christophe Hezode; Stephen Pianko; Stanislas Pol; Katherine Stuart; Edmund Tse; Fiona McPhee; Rafia Bhore; Maria Jesus Jimenez-Exposito; Alexander J Thompson

Journal article

Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3 )

Vincent Leroy, Peter Angus, Jean-Pierre Bronowicki, Gregory J Dore, Christophe Hezode, Stephen Pianko, Stanislas Pol, Katherine Stuart, Edmund Tse, Fiona McPhee, Rafia Bhore, Maria Jesus Jimenez-Exposito, Alexander J Thompson

Hepatology | WILEY | Published : 2016

DOI: 10.1002/hep.28473

University of Melbourne Researchers

Peter Angus Author Medicine - Austin Health

Alex Thompson Author Medicine - St Vincent's Hospital

Grants

Funding Acknowledgements

We thank Patricia Mendez and Melissa Harris for their contributions to the study conception, Kimberly Brown for contributing to the study execution, and Eric Y. Wong for contributing to the development of the manuscript. Editorial support was provided by Nick Fitch, Ph.D., of Articulate Science and was funded by Bristol-Myers Squibb.